Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs
TF Luscher, M Barton - Circulation, 2000 - Am Heart Assoc
The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin
peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects …
peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects …
Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management
DL Moraes, WS Colucci, MM Givertz - Circulation, 2000 - Am Heart Assoc
Pulmonary vascular resistance is frequently elevated in patients with chronic left ventricular
failure as a result of dysregulation of vascular smooth muscle tone and structural …
failure as a result of dysregulation of vascular smooth muscle tone and structural …
Endothelial barrier function and leukocyte transmigration in atherosclerosis
The vascular endothelium is a highly specialized barrier that controls passage of fluids and
migration of cells from the lumen into the vessel wall. Endothelial cells assist leukocytes to …
migration of cells from the lumen into the vessel wall. Endothelial cells assist leukocytes to …
Role of endothelin-1 in hypertension and vascular disease
EL Schiffrin - American journal of hypertension, 2001 - academic.oup.com
Abstract Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide and regulator of blood
flow that plays an important role in blood pressure (BP) elevation in some models of …
flow that plays an important role in blood pressure (BP) elevation in some models of …
Endothelin as a regulator of cardiovascular function in health and disease
The endothelins are a family of endothelium-derived peptides that possess characteristically
sustained vasoconstrictor properties. Endothelin-1 appears to be the predominant member …
sustained vasoconstrictor properties. Endothelin-1 appears to be the predominant member …
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH) …
Background Endothelin-receptor blockade provides haemodynamic benefit in experimental
and clinical heart failure. We aimed to measure the effects of long-term endothelin-blockade …
and clinical heart failure. We aimed to measure the effects of long-term endothelin-blockade …
Mechanisms of diabetic vasculopathy: an overview
Diabetes is commonly associated with both microvascular and macrovascular
complications. These vascular complications are accelerated in the context of systemic …
complications. These vascular complications are accelerated in the context of systemic …
Endothelin: 30 years from discovery to therapy
M Barton, M Yanagisawa - Hypertension, 2019 - Am Heart Assoc
Discovered in 1987 as a potent endothelial cell–derived vasoconstrictor peptide, endothelin-
1 (ET-1), the predominant member of the endothelin peptide family, is now recognized as a …
1 (ET-1), the predominant member of the endothelin peptide family, is now recognized as a …
Long-term neprilysin inhibition—implications for ARNIs
DJ Campbell - Nature Reviews Cardiology, 2017 - nature.com
Neprilysin has a major role in both the generation and degradation of bioactive peptides.
LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin …
LCZ696 (valsartan/sacubitril, Entresto), the first of the new ARNI (dual-acting angiotensin …
Endothelin
Y Kawanabe, SM Nauli - Cellular and Molecular Life Sciences, 2011 - Springer
Endothelin-1 is the most potent vasoconstrictor agent currently identified, and it was
originally isolated and characterized from the culture media of aortic endothelial cells. Two …
originally isolated and characterized from the culture media of aortic endothelial cells. Two …